115 related articles for article (PubMed ID: 8120556)
41. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Zinzani PL; Bendandi M; Magagnoli M; Gherlinzoni F; Merla E; Tura S
Ann Oncol; 1997 Apr; 8(4):379-83. PubMed ID: 9209669
[TBL] [Abstract][Full Text] [Related]
42. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
43. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Tsimberidou AM; Younes A; Romaguera J; Hagemeister FB; Rodriguez MA; Feng L; Ayala A; Smith TL; Cabanillas F; McLaughlin P
Cancer; 2005 Jul; 104(2):345-53. PubMed ID: 15948158
[TBL] [Abstract][Full Text] [Related]
44. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
45. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Zinzani PL; Magagnoli M; Bendandi M; Gherlinzoni F; Orcioni GF; Cellini C; Stefoni V; Pileri SA; Tura S
Ann Oncol; 2000 Mar; 11(3):363-5. PubMed ID: 10811507
[TBL] [Abstract][Full Text] [Related]
47. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
48. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
Magnano L; Montoto S; González-Barca E; Briones J; Sancho JM; Muntañola A; Salar A; Besalduch J; Escoda L; Moreno C; Domingo-Domenech E; Estany C; Oriol A; Altés A; Pedro C; Gardella S; Asensio A; Vivancos P; Fernández de Sevilla A; Ribera JM; Colomer D; Campo E; López-Guillermo A
Ann Hematol; 2017 Apr; 96(4):639-646. PubMed ID: 28101592
[TBL] [Abstract][Full Text] [Related]
50. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Emmanouilides C; Rosen P; Rasti S; Territo M; Kunkel L
Hematol Oncol; 1998 Sep; 16(3):107-16. PubMed ID: 10235069
[TBL] [Abstract][Full Text] [Related]
51. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Seymour JF; Grigg AP; Szer J; Fox RM
Ann Oncol; 2001 Oct; 12(10):1455-60. PubMed ID: 11762819
[TBL] [Abstract][Full Text] [Related]
52. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
53. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
[TBL] [Abstract][Full Text] [Related]
54. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Bishton MJ; Rule S; Wilson W; Turner D; Patmore R; Clifton-Hadley L; McMillan A; Lush R; Haynes A
Br J Haematol; 2020 Aug; 190(4):545-554. PubMed ID: 32150649
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Younes A; Rodriguez MA; McLaughlin P; North L; Sarris AH; Pate O; Hagemeister FB; Romaguera J; Preti A; Bachier C; Cabanillas F
Leuk Lymphoma; 1997 Jun; 26(1-2):77-82. PubMed ID: 9250790
[TBL] [Abstract][Full Text] [Related]
56. Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
Chim CS; Loong F; Ng WK; Kwong YL
Am J Clin Dermatol; 2008; 9(6):396-8. PubMed ID: 18973407
[TBL] [Abstract][Full Text] [Related]
57. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
[TBL] [Abstract][Full Text] [Related]
58. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
[TBL] [Abstract][Full Text] [Related]
59. Mitoxantrone, vincristine, and dexamethasone in patients with refractory lymphoma.
Paciucci PA; Crown JC; Holland JF
Am J Clin Oncol; 1989 Aug; 12(4):327-31. PubMed ID: 2667323
[TBL] [Abstract][Full Text] [Related]
60. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
